The results of the small study published in Nutrients showed that krill oil lasted 30 days [KO] The supplementation resulted in a 35.6% higher EPA level in the lipidome compared to fish oil [FO].
However, there were no differences between the groups for DHA, DPA, total long-chain omega-3 polyunsaturated fatty acids (PUFA), arachidonic acid, linoleic acid, or alpha-linolenic acid, scientists from Victoria University, Deakin University, Monash University, and the Baker Heart reported Diabetes Institute.
The study focused on the lipidoma, the complex collection of all lipid species in an organism.
“The use of lipidomics enabled the first clear observation of the differentiation between the plasma lipid molecular species that are influenced by KO and FO consumption in the steady state (ie after 30 days of supplementation),” the scientists write.
“This strongly suggests that the various lipid classes are contained in the dietary supplements (> 40% PC [phosphatidylcholine] Types for KO and> 99% TG [triglycerides] and DG [diglycerides] for FO) have a lasting influence on the lipid molecule species in the plasma. .
“KO had a significantly larger increase in 27 different lipid molecule species in seven phospholipid classes. In contrast, FO treatment showed significant effects on 17 different lipid molecular species from four phospholipid classes (two of which were different from those affected by KO). “.
The researchers said the physiological effects of these differences are unknown, “but they highlight that future studies of KO and FO comparisons should go beyond the omega-3s.”
“A nice start”.
Dr. William Harris, PhD of the University of South Dakota, independently commented on the study, saying that a director of the omega-3 testing firm OmegaQuant said the study was “a good start.”
“The lipidoma is much more complex than just the fatty acids,” he explained. “Cholesterol is part of the lipidome, every triglyceride and phospholipid is part of the lipidome. .
“This study is a good start, but it would have been unexpected if krill and fish oil had the same effect on lipidoma,” said Dr. Harris.
“This study lays a foundation for future research into the biological, physiological and clinical significance of the individual forms.” .
The researchers recruited 11 women between the ages of 18 and 50 to participate in their randomized cross-over study. The women were randomly given either fish oil (Natural FO, Swisse Wellness) or krill oil (Euphausia superba oil, Swisse Wellness) supplements for 30 days. This was followed by a four-week washout phase, which then went on to the other intervention. The fish oil and krill oil supplements provided EPA doses of 786 mg / day and 759 mg / day and DHA doses of 470 mg / day and 420 mg / day, respectively.
The results showed that the relAUC, or the relative area under the curve, for EPA on day 15 was 23.9% higher for krill oil supplementation and was 35.6% higher on day 30 than for the fish oil group.
The researchers also found that krill oil supplementation had increased cholesterol levels slightly and decreased phosphatidylserine (PS) levels.
“This study shows that KO and FO have no equivalent effects on plasma lipidoma,” they wrote.
“The plasma EPA was significantly higher after the KO treatment compared to the FO treatment. Significant plasma lipidome remodeling was observed between KO and FO treatments, with their effects on different plasma lipid molecular species being significantly different, with changes in lipid species not being limited to those enriched with omega-3 PUFA were. .
“Further studies will be needed to determine whether the differences observed here have biological consequences / health benefits.”
The study was funded by Victoria University’s College of Health and Biomedicine and the Victorian State Government’s Operational Infrastructure Support Scheme.
2020, 12 (9), 2804; doi: 10.3390 / nu12092804
“Krill Oil Has Different Effects on Plasma Lipidoma After 30 Days of Supplementation in Healthy Women Compared to Fish Oil: A Randomized Controlled and Crossover Study”
Authors: PJ Meikle et al.